CN104148018A - 抗体亲和纯化材料及其用途 - Google Patents
抗体亲和纯化材料及其用途 Download PDFInfo
- Publication number
- CN104148018A CN104148018A CN201310178055.7A CN201310178055A CN104148018A CN 104148018 A CN104148018 A CN 104148018A CN 201310178055 A CN201310178055 A CN 201310178055A CN 104148018 A CN104148018 A CN 104148018A
- Authority
- CN
- China
- Prior art keywords
- antibody
- affinity purification
- parting material
- affine parting
- buffer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 59
- 238000001261 affinity purification Methods 0.000 title description 39
- 239000011159 matrix material Substances 0.000 claims abstract description 10
- 238000011091 antibody purification Methods 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 10
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 claims description 7
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- FXNSVEQMUYPYJS-UHFFFAOYSA-N 4-(2-aminoethyl)benzenesulfonamide Chemical compound NCCC1=CC=C(S(N)(=O)=O)C=C1 FXNSVEQMUYPYJS-UHFFFAOYSA-N 0.000 claims description 4
- ABJQKDJOYSQVFX-UHFFFAOYSA-N 4-aminonaphthalen-1-ol Chemical compound C1=CC=C2C(N)=CC=C(O)C2=C1 ABJQKDJOYSQVFX-UHFFFAOYSA-N 0.000 claims description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- AUFJTVGCSJNQIF-UHFFFAOYSA-N 2-Amino-4,6-dihydroxypyrimidine Chemical compound NC1=NC(O)=CC(=O)N1 AUFJTVGCSJNQIF-UHFFFAOYSA-N 0.000 claims description 3
- UENRXLSRMCSUSN-UHFFFAOYSA-N 3,5-diaminobenzoic acid Chemical compound NC1=CC(N)=CC(C(O)=O)=C1 UENRXLSRMCSUSN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims 7
- 239000012148 binding buffer Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000012930 cell culture fluid Substances 0.000 claims 1
- 239000003480 eluent Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 abstract description 8
- 238000000926 separation method Methods 0.000 abstract description 7
- 238000000746 purification Methods 0.000 abstract description 3
- 125000006850 spacer group Chemical group 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000011068 loading method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000013014 purified material Substances 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 229940125645 monoclonal antibody drug Drugs 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 4
- HHRFWSALGNYPHA-UHFFFAOYSA-N [N].C1CNCCN1 Chemical class [N].C1CNCCN1 HHRFWSALGNYPHA-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 101710153593 Albumin A Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310178055.7A CN104148018B (zh) | 2013-05-14 | 2013-05-14 | 抗体亲和纯化材料及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310178055.7A CN104148018B (zh) | 2013-05-14 | 2013-05-14 | 抗体亲和纯化材料及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104148018A true CN104148018A (zh) | 2014-11-19 |
CN104148018B CN104148018B (zh) | 2018-04-20 |
Family
ID=51873758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310178055.7A Expired - Fee Related CN104148018B (zh) | 2013-05-14 | 2013-05-14 | 抗体亲和纯化材料及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104148018B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114235990A (zh) * | 2021-11-29 | 2022-03-25 | 宁夏医科大学 | 一种结核病血清标志物筛选方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
CN1200680A (zh) * | 1995-09-20 | 1998-12-02 | 诺沃挪第克公司 | 新亲合配位体及其应用 |
CN1558898A (zh) * | 2001-08-10 | 2004-12-29 | ��Ұ����ҩ��ʽ���� | 抗病毒药 |
CN101605794A (zh) * | 2006-08-21 | 2009-12-16 | 健泰科生物技术公司 | 氮杂苯并呋喃基化合物及使用方法 |
CN101760355A (zh) * | 2008-12-17 | 2010-06-30 | 气体产品与化学公司 | 用于CoWP和多孔电介质的湿清洁组合物 |
-
2013
- 2013-05-14 CN CN201310178055.7A patent/CN104148018B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
CN1200680A (zh) * | 1995-09-20 | 1998-12-02 | 诺沃挪第克公司 | 新亲合配位体及其应用 |
CN1558898A (zh) * | 2001-08-10 | 2004-12-29 | ��Ұ����ҩ��ʽ���� | 抗病毒药 |
CN101605794A (zh) * | 2006-08-21 | 2009-12-16 | 健泰科生物技术公司 | 氮杂苯并呋喃基化合物及使用方法 |
CN101760355A (zh) * | 2008-12-17 | 2010-06-30 | 气体产品与化学公司 | 用于CoWP和多孔电介质的湿清洁组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114235990A (zh) * | 2021-11-29 | 2022-03-25 | 宁夏医科大学 | 一种结核病血清标志物筛选方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104148018B (zh) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5525519A (en) | Method for isolating biomolecules from a biological sample with linear polymers | |
CN101059487B (zh) | 一种免疫亲和色谱柱及其在净化喹诺酮类药物中的应用 | |
JP2009500604A (ja) | IgGの選択的吸着のためのクロマトグラフィー用吸着剤としての[1,2,4]トリアゾロ[1,5−a]ピリミジン誘導体 | |
CN1972746B (zh) | 分离基质和纯化方法 | |
CN102574102A (zh) | 用于结合蛋白质和肽的特异性吸附剂及使用其的分离方法 | |
CN103575889B (zh) | 一种检测万古霉素的试纸条及方法 | |
CN104718450B (zh) | 抗体精制用阳离子交换色谱法载体及抗体医药的制程中生产的抗体单体与其聚合物的分离法 | |
CN103941000A (zh) | 一种检测磺胺类药物和氟喹诺酮类药物的试纸条及方法 | |
Kish et al. | Peptide-based affinity adsorbents with high binding capacity for the purification of monoclonal antibodies | |
CN105837687B (zh) | 一种抗TNF-α类单克隆抗体的层析方法 | |
Reese et al. | Novel peptide ligands for antibody purification provide superior clearance of host cell protein impurities | |
JP2009531653A (ja) | タンパク質精製用の吸着体 | |
CN103468735B (zh) | 重组华溪蟹金属硫蛋白(rcMT)及其单克隆抗体的制备 | |
CN100574840C (zh) | 免疫球蛋白的纯化 | |
CN103288965A (zh) | 一种多氯联苯单克隆抗体的制备方法 | |
CN104148018A (zh) | 抗体亲和纯化材料及其用途 | |
CN112114074B (zh) | 乳铁蛋白适配体亲和柱及其制备方法与应用 | |
CN112094351B (zh) | 一种抗vegfr-2单克隆抗体的检测性抗体、应用及检测方法 | |
CN103293304B (zh) | 一种检测磺胺类药物的试剂盒及方法 | |
CN100402522C (zh) | 一种净化常山酮的方法及其专用免疫亲和色谱柱 | |
CN101433825B (zh) | 自动物样品中提取盐霉素类化合物的方法及其专用免疫亲和吸附剂 | |
CN203535050U (zh) | 检测磺胺类药物和氟喹诺酮类药物的试纸条 | |
WO2015099550A1 (en) | Magnetic liquid-liquid extraction for purification and partitioning of substances | |
CN202735353U (zh) | 检测万古霉素的试纸条 | |
CN106754732A (zh) | 喹乙醇杂交瘤细胞株和单克隆抗体及复合免疫吸附剂和免疫亲和柱与试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: MA GUIJUN Effective date: 20141029 Owner name: SHANGHAI HENGZHEN INDUSTRY CO., LTD. Free format text: FORMER OWNER: LI RONGXIU Effective date: 20141029 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200240 MINHANG, SHANGHAI TO: 200131 PUDONG NEW AREA, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141029 Address after: 200131 Shanghai city east foot of Pudong New Area Free Trade Zone No. 458 Road 5 Room 518 Applicant after: SHANGHAI HENGZHEN INDUSTRIAL CO., LTD. Address before: 200240 School of life sciences, No. 800 Dongchuan Road, Shanghai, Minhang District 4-405 Applicant before: Li Rongxiu Applicant before: Ma Guijun |
|
DD01 | Delivery of document by public notice |
Addressee: Liu Yue Document name: Notification of Passing Examination on Formalities |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180420 Termination date: 20190514 |